Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative

ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment.

“Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD intervention, prevention and treatment,” stated Dr. Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular Neuroimaging at Imperial College London. “We look forward to joining other Industry leaders on the private partner scientific board to contribute to the success of this outstanding initiative.”

Invicro is an industry leader in neuroimaging and the application of PET and MRI imaging for AD, which fully aligns with ADNI’s mission. Having an established pedigree in coordinating worldwide multi-center Phase II and III clinical imaging trials, Invicro provides management and oversight of radiotracer supply along with centralized data management and advanced analysis of imaging endpoints in drug development and clinical research for AD.

“On behalf of Invicro, we are pleased to be part of such an exciting and progressive initiative for the advancement of AD research,” said Dr. Marek, Distinguished Scientist for Invicro. “Invicro’s research and novel biomarkers have been significant for the progression of clinical trials in AD and neurodegenerative disorders.”

The ADNI-PPSB, convened by the Foundation for the National Institutes of Health, serves as a forum for open dialogue as it relates to the project’s progress and new trends in research and development within the field of Alzheimer’s disease. “The FNIH is delighted that Invicro is joining the ADNI-PPSB, which creates a pre-competitive forum where partners can participate in study-related scientific exchanges,” said Joseph Menetski, Ph.D., Associate Vice President, FNIH. “We welcome Invicro’s expertise in neuroimaging that will contribute to ADNI’s goal of defining the progression of Alzheimer’s disease.”

About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 and today has offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology companies and top research universities. Invicro’s multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drug across all stages of the drug development pipeline (Phase 0-IV), leveraging all imaging modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®.

Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Visit www.invicro.com for more information

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005629/en/